Healthcare professionals (HCPs) are not only worried about how they will get through COVID-19, they’re also concerned about the long-term well-being of their patients, according to a new survey published today by Fingerpaint.
The Fingerpaint COVID-19 HCP Survey showed that 59% percent of HCPs were worried about their patients not being diagnosed in a timely manner, and 58% believe their patients will not be able to obtain previously prescribed in-office/outpatient care. More than half of those surveyed (53%) don’t think their patients have the ability to utilize telemedicine and will not be able to refill their medications.
They believe the pandemic will have a long-term impact on their practice. In fact, 59% of them believe they won’t feel more hopeful about the current COVID-19 situation for at least 2 to 6 months.
“As brands refine their marketing efforts, it is important to have a deep understanding of what’s keeping HCPs awake at night and how this pandemic is impacting them and their patients,” said Michelle Petroff, head of Fingerpaint’s Conshohocken, PA, office. “Many of the HCPs reached in this survey are not just worried about the short-term issues, but are looking for long-term solutions.”
There was positive news in the survey. While overall 66% of HCPs reported feeling anxious about COVID-19 as it applies to their practice, only 5% went as far as saying that they feel defeated.
The survey link was sent in an email to about 16,000 contacts. Respondents were screened to ensure their status as healthcare professionals who reside in the United States, were board-certified in their specialty, and had a minimum of 4 and maximum of 40 years’ practice experience. A total of 116 healthcare professionals completed the online survey during the week of March, 2020.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.